Life Sciences

Setback for Bayer as Promising Anti-Clotting Drug Trials Halted

Setback for Bayer as Promising Anti-Clotting Drug Trial...

Nov 22, 2023

In a significant setback for Germany’s pharmaceutical giant Bayer, the company h...

Karuna Therapeutics Phase 1b Trial Results Reinforce Cardiovascular Safety of Schizophrenia Treatment KarXT

Karuna Therapeutics Phase 1b Trial Results Reinforce Ca...

Nov 22, 2023

The Phase 1b unrestricted-label, eight-week residential trial meant to assess t...

FDA Expresses Doubt Over Merck’s Cough Candidate

FDA Expresses Doubt Over Merck’s Cough Candidate

Nov 18, 2023

Merck & Co. is racing against the clock to launch the first medication for chron...

Gilead gives Arcellx $285 million to extend agreement for BCMA cell treatment

Gilead gives Arcellx $285 million to extend agreement f...

Nov 18, 2023

Gilead Sciences subsidiary, Kite Pharma, is allocating $285 million towards adva...

Teva Secures $100M Funding to Expedite Schizophrenia Drug Development

Teva Secures $100M Funding to Expedite Schizophrenia Dr...

Nov 16, 2023

Teva has tapped into royalty funding to speed up the development of an antipsych...

New York University Study Finds Prominent Breakthrough for Pain Management; Outperforms Pain Drug

New York University Study Finds Prominent Breakthrough ...

Nov 16, 2023

Researchers at New York University have made an important discovery in the field...

Pfizer’s Cost-Cutting Measures Impact UK’s Sandwich Site, Leading to Job Loss for 500 Employees

Pfizer’s Cost-Cutting Measures Impact UK’s Sandwich Sit...

Nov 16, 2023

Earlier this month, Pfizer, the pharmaceutical giant, extended its cost-cutting ...

Novo Says Weight Loss Alone Isn’t to Thank For Wegovy’s Heart Benefits

Novo Says Weight Loss Alone Isn’t to Thank For Wegovy’s...

Nov 16, 2023

Novo Nordisk unveiled fresh findings at a prominent medical conference, indicati...

Selecta and Cartesian strengthen funding for the objectives of autoimmune cell treatment in reverse merger

Selecta and Cartesian strengthen funding for the object...

Nov 14, 2023

Selecta Biosciences is embarking on a strategic collaboration with Cartesian, st...

AstraZeneca Looking For Another Liver Cancer Green Light For Imfinzi

AstraZeneca Looking For Another Liver Cancer Green Ligh...

Nov 14, 2023

After last year’s nod, AstraZeneca’s flagship PD-L1 Imfinzi is demonstrating eff...

Izervay Demonstrates Prolonged Efficacy in GATHER2 Study Amidst Competitive Landscape

Izervay Demonstrates Prolonged Efficacy in GATHER2 Stud...

Nov 10, 2023

Astellas Pharmaceuticals made a substantial $5.9 billion investment earlier this...

Vor Bio’s ADC therapy shows encouraging engraftment with reduced toxicity

Vor Bio’s ADC therapy shows encouraging engraftment wit...

Nov 10, 2023

Newly released findings from Vor Bio showcase the effective integration of their...

AstraZeneca abandons phase 2 sickle cell medication and pays $185 million to rejoin the oral obesity gold rush market

AstraZeneca abandons phase 2 sickle cell medication and...

Nov 10, 2023

AstraZeneca is reentering the obesity drug market through a strategic acquisitio...

After success with its BabySat system, Owlet gains FDA clearance for its Dream Sock

After success with its BabySat system, Owlet gains FDA ...

Nov 10, 2023

Owlet, the innovative baby monitoring system company, is celebrating a significa...

Federal Court Rejects Alvogen’s Bid for FDA Approval of Bausch’s Xifaxan Version

Federal Court Rejects Alvogen’s Bid for FDA Approval of...

Nov 8, 2023

Salix Pharmaceuticals, a subsidiary of Bausch Health, has emerged victorious in ...

Atara Turns to Pierre Fabre in Huge $640M T-Cell Deal

Atara Turns to Pierre Fabre in Huge $640M T-Cell Deal

Nov 8, 2023

Atara Biotherapeutics is looking to Pierre Fabre Laboratories, the same collabor...

18
19
20
21
22